Browsing ICR Divisions by author "Haider, Syed"
Now showing items 21-40 of 41
-
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.
Jungwirth, U; van Weverwijk, A; Evans, RJ; Jenkins, L; Vicente, D; et al. (NATURE PORTFOLIO, 2021-06-10)Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ... -
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, H; Sipos, O; Parker, JS; Hoadley, KA; Quist, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-15)PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ... -
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.
Lord, SR; Cheng, W-C; Liu, D; Gaude, E; Haider, S; et al. (CELL PRESS, 2018-11-06)Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study ... -
Landscape of transcriptomic interactions between breast cancer and its microenvironment.
Fox, NS; Haider, S; Harris, AL; Boutros, PC (NATURE PUBLISHING GROUP, 2019-07-15)Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, ... -
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones, E; Raghunandan, M; Robbez-Masson, L; Magraner-Pardo, L; Alaguthurai, T; et al. (Elsevier BV, 2024-01-19)BACKGROUND: Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically validated, mechanisms of resistance have been proposed, ... -
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski, A; Francica, P; Lingg, L; Mutlu, M; Stok, C; et al. (CELL PRESS, 2023-05-30)The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity ... -
Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, (NATURE PORTFOLIO, 2020-02-06)Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of ... -
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon, RM; Muirhead, G; Krastev, DB; Adam, J; Morel, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2019-03-01)The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA ... -
Pol theta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Zatreanu, DA; Robinson, HMR; Alkhatib, O; Boursier, M; Finch, H; et al. (AMER ASSOC CANCER RESEARCH, 2021-12-01) -
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu, D; Robinson, HMR; Alkhatib, O; Boursier, M; Finch, H; et al. (NATURE RESEARCH, 2021-06-17)To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ... -
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment.
Stevenson, J; Barrow-McGee, R; Yu, L; Paul, A; Mansfield, D; et al. (NATURE PORTFOLIO, 2021-03-05)In breast cancer (BC), detecting low volumes of axillary lymph node (ALN) metastasis pre-operatively is difficult and novel biomarkers are needed. We recently showed that patient-derived ALNs can be sustained ex-vivo using ... -
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
Khalique, S; Nash, S; Mansfield, D; Wampfler, J; Attygale, A; et al. (MDPI, 2021-07-30)Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian cancer characterised by a high frequency of loss-of-function ARID1A mutations and a poor response to chemotherapy. Despite their generally low ... -
Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study.
Barrow-McGee, R; Procter, J; Owen, J; Woodman, N; Lombardelli, C; et al. (WILEY, 2020-03-01)Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and ... -
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland, P; Saville, H; Wai, PT; Curnow, L; Muirhead, G; et al. (NATURE PORTFOLIO, 2023-08-01)SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1MUT) cells ... -
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Bajrami, I; Walker, C; Krastev, DB; Weekes, D; Song, F; et al. (NATURE PORTFOLIO, 2021-11-08)PARP enzymes utilise NAD+ as a co-substrate for their enzymatic activity. Inhibition of PARP1 is synthetic lethal with defects in either BRCA1 or BRCA2. In order to assess whether other genes implicated in NAD+ metabolism ... -
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Llorca-Cardenosa, MJ; Aronson, LI; Krastev, DB; Nieminuszczy, J; Alexander, J; et al. (AMER ASSOC CANCER RESEARCH, 2022-11-02)UNLABELLED: Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed ... -
SOX11 promotes invasive growth and ductal carcinoma in situ progression.
Oliemuller, E; Kogata, N; Bland, P; Kriplani, D; Daley, F; et al. (WILEY, 2017-10-01)Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary ... -
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.
Yeow, ZY; Lambrus, BG; Marlow, R; Zhan, KH; Durin, M-A; et al. (NATURE PORTFOLIO, 2020-09-17)Genomic instability is a hallmark of cancer, and has a central role in the initiation and development of breast cancer1,2. The success of poly-ADP ribose polymerase inhibitors in the treatment of breast cancers that are ... -
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing.
Chong, IY; Starling, N; Rust, A; Alexander, J; Aronson, L; et al. (MDPI, 2021-01-09)UNLABELLED: 1. BACKGROUND: The application of massively parallel sequencing has led to the identification of aberrant druggable pathways and somatic mutations within therapeutically relevant genes in gastro-oesophageal ... -
Therapy-induced normal tissue damage promotes breast cancer metastasis.
Perkins, DW; Steiner, I; Haider, S; Robertson, D; Buus, R; et al. (CELL PRESS, 2024-01-19)Disseminated tumor cells frequently exhibit a period of dormancy, rendering them chemotherapy insensitive; conversely, the systemic delivery of chemotherapies can result in normal tissue damage. Using multiple mouse and ...